Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.10 -3.2% 93.90 94.10 94.40 98.00 94.00 96.00 1,801,089 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 -78.8 -7.1 - 998

Ip Share Discussion Threads

Showing 2101 to 2124 of 2300 messages
Chat Pages: 92  91  90  89  88  87  86  85  84  83  82  81  Older
DateSubjectAuthorDiscuss
18/11/2020
15:41
The trading does seem relentless. Based on previous consolidation zones, the stock was due a rerate to a higher trading range. Each zone is 41-42 sessions long. Since the uptrend began the ranges are 11, 9.6, 7.6, 8.1 Assuming we are entering a new trading range starting at 85, the upper end should be around 93-94.
bamboo2
18/11/2020
14:51
Upward momentum continues - topped up again today.
masurenguy
18/11/2020
14:28
Wet, agree. A few weeks ago we've seen Gordon Sanghera suggest that the valuation of the ONT will increase in size tenfold in five years, so valued at approx £8bn. This means IPGroup's 15% of ONT will be worth significantly more than IPO's current MCAP.
bamboo2
18/11/2020
13:53
ONT applications go far beyond COVID-19 testing, market hasn't fully registered this yet. hxxps://www.nanowerk.com/nanotechnology-news2/newsid=56574.php
wetpantz
17/11/2020
21:20
8m on the volume. Any chance of a holdings rns?
bamboo2
14/11/2020
13:06
Not at all. No way should that capital be paid out. It should be allocated to new investments.
p1nkfish
14/11/2020
12:05
So pink, after me posting the very same occasionally over the last 6 months to very much criticism from yourself, you seem to have come round to the same view now.Oh well, better late than never.
pierre oreilly
14/11/2020
09:44
p!nk, email the management. Ask for an update on the discussions re buyback/dividend. If you don't I will! Daily volume is stepping up. Still no holdings rns's, so have to assume accumulation in background continues.
bamboo2
13/11/2020
23:47
The cash stands out like a sore thumb and with yields so low what's next and when? Hanging about with that in the bank........it's eroding in value unless IPO see some crash or other ahead when its purchasing power will have increased. 12 months from now surely it will have largely been allocated? Puzzled.
p1nkfish
06/11/2020
08:23
Thanks bamboo2 - a small holding for me in the speculative section of my portfolio. Good luck with your trading strategy.
masurenguy
05/11/2020
17:41
Hi Mas. Hope it works out for you. The trend looks quite clear. I am trading this share, but maintain a basic holding most of the time. Trading an uptrend is reasonably safe, and can make things a bit more interesting. Over recent sessions I have bought a substantial holding which I have sold into the strength today.
bamboo2
05/11/2020
14:45
Topped up here today.
masurenguy
03/11/2020
17:26
Investors Meeting 10.30 am 4/11/2020 Canberra [I think this is 11.30pm 3/11/2020, ie this evening] IP Group Australia Showcase 2020 - Session 2 Description Physical Sciences - Transformational Technology Https://www.ipgroupanz.com/events Follow link and register if interested.
bamboo2
31/10/2020
14:05
Price touched the 50sma. Hope the bounce lasts.
bamboo2
30/10/2020
09:00
Re Liquid biopsy. Cyclomics. Detecting cancer, before it's too late... Cyclomics is a Dutch startup company founded in 2018 by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology. Mission – Accurate measurement of cancer recurrence and monitoring of treatment responses are important clinical needs in cancer diagnostics. The limitations of existing (imaging-based) methods poses a significant impediment to effective (re-)treatment and overall survival. The mission of Cyclomics is to address this challenge through an innovative solution for early cancer detection called CyclomicsSeq. This solution consists of a new diagnostic kit that can disrupt the cancer diagnostics market and clinical practice by enabling fast and reliable results, and delivering superior performance to standard radiological and/or physical examination alone. CyclomicsSeq’s first application will be for head and neck cancers (HNC), where monitoring of treatment response and recurrence disease is essential for improving survival. Need to address – Recurrent disease after initial remission is a main cause of cancer death, warranting early detection as key to improving patient outcome and quality of life. This need is particularly strong in head and neck cancer (HNC), where 150,000 new cases arise every year in the EU. Radiological imaging is the current standard in detecting HNC tumor recurrence, but suffers from low sensitivity and specificity, revealing relapsed tumor lesions only when they have progressed too far for curative treatment strategies. In addition, treatment response monitoring is key for HNC treatment, in order to adjust drug dose or change drug choice. Solution – Cyclomics has developed a ground-breaking solution that enables reliable, fast and ultra- sensitive detection of cancer recurrence. This is achieved by detection of ctDNA, a reliable biomarker for determining presence or absence of cancer, which can be non-invasively obtained from a blood sample (liquid biopsy). Since 90% of HNC patients carry specific oncogenic DNA mutations in the gene TP53, the first application of this novel technology is focused on recurring HNC. To this end, Cyclomics is developing CyclomicsSeq TP53: an in vitro diagnostic (IVD) kit integrating an innovative sequencing methodology and state-of- the-art analysis software package. The IVD is designed to seamlessly integrate into existing clinical workflows while providing superior diagnostics for clinical decision making. In the long-term, we will expand the Cyclomics’ solution to other cancer types harboring TP53 mutations. The key advantages of Cyclomics’ solution are: Cutting-edge technology: it will be the first IVD available for 3rd generation sequencing platforms, which is disrupting the sequencing arena by significantly driving down sequencing costs. Non-invasive test: a vial of blood is all that it is needed. Point of care: the technology can be implemented anywhere, without the need of investing in costly infrastructure. Fast: results are ready in 3 days. Sensitive: single-molecule resolution and nearly 100% accuracy. Https://www.cyclomics.com/ Https://nanoporetech.com/resource-centre/cyclomics-ultra-sensitive-nanopore-sequencing-cell-free-tumor-dna
bamboo2
30/10/2020
07:43
edwardt, yes. I don't know much about Oxehealth, but presentation was impressive, with good sales this year and quite rapid expansion next. The main reason to watch was to see Gordon Sanghera of Oxford Nanopore. He comes across as very serious and sure of himself. He sees the co. at the heart of the Genomic revolution, with diagnostics becoming a larger part of the business. Liquid biopsy for early detection of cancer, in partnership with other co's. Cyclomics is an early example. Sees ONT increasing in size tenfold in five years, so valued at approx £8bn [on that basis, without dilution, 15% of ONT will be worth more than the current MCAP of IPO] The Q&A session ran out of time, but they are hoping to upload some on the website
bamboo2
29/10/2020
19:28
Anyone listen in?
edwardt
29/10/2020
09:51
This afternoon 4PM IP Group plc (LSE: IPO) ("IP Group" or "the Company" or "the Group"), the developer of intellectual property-based businesses, is pleased to announce that it will be hosting a webinar on the role that science and innovation has to play in building resilience in health systems. The webinar, which will take place on Thursday 29 October at 16:00GMT, will feature short presentations from Dr Gordon Sanghera, CEO of portfolio company Oxford Nanopore Technologies, and Hugh Lloyd-Jukes, CEO of portfolio company Oxehealth, detailing how their companies have innovated in the battle against the pandemic. IP Group is committed to clear and open communication with stakeholders and attendees will have the opportunity to ask questions as part of the event. For more details or to register as a participant please visit Https://www.ipgroupplc.com/events Https://us02web.zoom.us/webinar/register/WN_8XLGaRCIQu2kx-kks--kmQ
bamboo2
28/10/2020
12:23
Moray Wright of Parkwalk discusses the business. Around 130 co's with 30 exits generating a return of approx 25% [since 2009] 16 Employees. Assets approx £325m Https://globaluniversityventuring.com/leadership-series-moray-wright/
bamboo2
27/10/2020
14:33
The 290,000 shares the group have in CWR are out of lock-in, so assuming they are now gone, that's another £2m to add to the cash pile. :-)
bamboo2
25/10/2020
17:15
Part of report from a while ago... ttps://www.ft.com/content/d4f3f56f-9d0c-4e9f-bc34-1be4c390b212' target='window'>https://www.ft.com/content/d4f3f56f-9d0c-4e9f-bc34-1be4c390b212 ...Privately held Oxford Nanopore, meanwhile, has just completed a funding round at the same valuation as in January’s pre-Covid era, roughly £1.7bn, according to number-crunchers at Numis. When it raised cash in 2018, the group was valued at £1.5bn.  The university spinout strictly specialises in DNA sequencing technology, not diagnostics. But its gene-reading machines have been used to sequence the Sars-Cov-2 virus, helping track its spread. And it has diversified into testing too. On Tuesday listed investor IP Group — which was a founder backer — revealed Nanopore had secured a £113m UK government contract for its LamPORE Covid tests.  Analysts are all excited about a potential Nanopore IPO. Jefferies’ Ken Rumph reckons the company could be worth $6bn. Talk of a float last year was premature, everyone now agrees, since the company needed more time to demonstrate commercial applications of its biotech and that it could earn recurring revenues.  Maybe next year. But then investors have been hoping for an IPO for years. Lansdowne Partners, Neil Woodford and Invesco were meant to be patient backers of the private company. But they have since sold, or been forced to sell, large stakes. IP Group — which was also backed by Lansdowne, Woodford and Invesco — also trimmed its stake. It is now down to 15 per cent.  Nanopore’s investors shouldn’t lose heart. This year’s fundraisings, which set a current price for the group, have been undermined and overshadowed by the plight of its early supporters. Its valuation will catch up with the Covid-19 bump. Investors who can hang in there should. Those who don’t have access to the private company should take a punt on IP Group...
bamboo2
25/10/2020
16:38
The sale of CWR means that IPGroup can now focus on Bramble Energy [24.2%] and RFC Power [26.5%]. Both of these constituent companies have team members that originate from the same institution as CWR, Imperial College London. Some were founders of CWR. The companies also share some management. Https://www.brambleenergy.com/ Https://www.rfcpower.com/team
bamboo2
22/10/2020
19:24
The successful test of the support line at 80 this morning looks positive.
bamboo2
22/10/2020
18:12
cord, I was looking at quite a few different funds this morning and probably got confused. dyor!
bamboo2
Chat Pages: 92  91  90  89  88  87  86  85  84  83  82  81  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210128 06:15:23